82 related articles for article (PubMed ID: 20428637)
1. Effectiveness of highly active antiretroviral therapy (HAART) used concomitantly with rifampicin in patients with tuberculosis and AIDS.
Sant'Anna FM; Velasque L; Costa MJ; Schmaltz CA; Morgado MG; Lourenço MC; Grinsztejn B; Rolla VC
Braz J Infect Dis; 2009 Oct; 13(5):362-6. PubMed ID: 20428637
[TBL] [Abstract][Full Text] [Related]
2. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
3. Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Vibhagool A
J Infect; 2006 Mar; 52(3):188-94. PubMed ID: 15992932
[TBL] [Abstract][Full Text] [Related]
4. Influence of treatment and immunological recovery on tuberculosis relapses in HIV-infected patients.
Lopez-Cortes LF; Marin-Niebla A; Lopez-Cortes LE; Villanego I; Rodriguez-Diez M; Pascual-Carrasco R
Int J Tuberc Lung Dis; 2005 Dec; 9(12):1385-90. PubMed ID: 16466062
[TBL] [Abstract][Full Text] [Related]
5. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
[TBL] [Abstract][Full Text] [Related]
6. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
Moore DM; Hogg RS; Yip B; Wood E; Harris M; Montaner JS
HIV Med; 2006 Jul; 7(5):311-6. PubMed ID: 16945076
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
Manosuthi W; Tantanathip P; Chimsuntorn S; Eampokarap B; Thongyen S; Nilkamhang S; Sungkanuparph S
Int J Infect Dis; 2010 Nov; 14(11):e1013-7. PubMed ID: 20880733
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy.
Dheda K; Lampe FC; Johnson MA; Lipman MC
J Infect Dis; 2004 Nov; 190(9):1670-6. PubMed ID: 15478074
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of anti-tuberculosis treatment among patients receiving highly active antiretroviral therapy at Vihiga district hospital in 2007.
Kwange SO; Budambula NL
Indian J Med Microbiol; 2010; 28(1):21-5. PubMed ID: 20061758
[TBL] [Abstract][Full Text] [Related]
12. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
[TBL] [Abstract][Full Text] [Related]
13. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients.
Maggiolo F; Ripamonti D; Gregis G; Quinzan G; Callegaro A; Arici C; Ravasio L; Suter F
Antivir Ther; 2003 Aug; 8(4):339-46. PubMed ID: 14518703
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral treatment outcome following genotyping in Thai children who failed dual nucleoside reverse transcriptase inhibitors.
Bunupuradah T; Suntarattiwong P; Li A; Sirivichayakul S; Pancharoen C; Boonrak P; Puthanakit T; Kerr SJ; Ruxrungtham K; Chotpitayasunondh T; Hirschel B; Ananworanich J;
Int J Infect Dis; 2010 Apr; 14(4):e311-6. PubMed ID: 19699673
[TBL] [Abstract][Full Text] [Related]
15. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
Potard V; Rey D; Mokhtari S; Frixon-Marin V; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
Antivir Ther; 2007; 12(3):317-24. PubMed ID: 17591021
[TBL] [Abstract][Full Text] [Related]
16. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Boulle A; Van Cutsem G; Cohen K; Hilderbrand K; Mathee S; Abrahams M; Goemaere E; Coetzee D; Maartens G
JAMA; 2008 Aug; 300(5):530-9. PubMed ID: 18677025
[TBL] [Abstract][Full Text] [Related]
19. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Kirk O; Lundgren JD; Pedersen C; Mathiesen LR; Nielsen H; Katzenstein TL; Obel N; Gerstoft J
Antivir Ther; 2003 Dec; 8(6):595-602. PubMed ID: 14760893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
